SCHEMBL20127210

SCHEMBL20127210

c1ccc(-c2nc(-c3ccc(C4(c5ccccc5)c5ccccc5-c5c4ccc4ccccc54)cc3)nc(-c3ccc4ccccc4c3)n2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
TP53 P04637 2/20 0.36
HSD17B10 Q99714 2/20 0.36
CYP1A2 P05177 1/20 0.36
MAPT P10636 5/20 0.35
LMNA P02545 2/20 0.35
OPRK1 P41145 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
GPR84 Q9NQS5 1/20 0.34
ADORA2A P29274 2/20 0.34
ADORA1 P30542 2/20 0.34
HPGD P15428 2/20 0.33
ATM Q13315 2/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22868581 0.94 MEN1 (0.37) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL20127170 0.94 MAPT (0.40) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL21394241 0.93 MAPT (0.39) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL20127193 0.93 MAPT (0.39) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL20127194 0.93 MAPT (0.39) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL21394019 0.93 MAPT (0.39) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL21394016 0.93 MAPT (0.39) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL21394113 0.93 MAPT (0.39) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL21394116 0.93 MAPT (0.39) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL21394307 0.92 MAPT (0.35) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10745362-B2 Heterocyclic compound and organic light emitting device comprising same LG CHEM, LTD. (KR) 2020-08-18 US disclosed
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM LTD. (KR) 2018-05-10 US disclosed
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM LTD. (KR) 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10745362-B2 Heterocyclic compound and organic light emitting device comprising same CRY1, CRY2, PER2 SMN1; SMN2 4089/4885MEN1 847/4885KMT2A 714/4885
US-20180127385-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME CRY1, CRY2, PER2 SMN1; SMN2 4089/4885MEN1 847/4885KMT2A 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.